Online inquiry

IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3860MR)

This product GTTS-WQ3860MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3860MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13536MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ10413MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ7582MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ15808MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ11774MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ10952MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ13461MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ14543MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SAR156597
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW